Is Revolution Medicines, Inc. (RVMD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.8% / 30% | 10.4% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.8% / 33% | 10.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 6.7% / 33% | 86.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.8% / 33% | 10.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 6.7% / 33% | 86.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -58.1% | |
| Return on Assets (ROA) | -30.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$898M |
| Free Cash Flow | -$914M |
| Total Debt | $159M |
| Debt-to-Equity | 26.2 |
| Current Ratio | 7.1 |
| Total Assets | $2.4B |
Price & Trading
| Last Close | $93.21 |
| 50-Day MA | $100.91 |
| 200-Day MA | $65.91 |
| Avg Volume | 3.3M |
| Beta | 1.0 |
|
52-Week Range
$29.17
| |
About Revolution Medicines, Inc. (RVMD)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Revolution Medicines, Inc. (RVMD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Revolution Medicines, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Revolution Medicines, Inc.'s debt ratio?
Revolution Medicines, Inc.'s debt ratio is 0.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.7%.
What are Revolution Medicines, Inc.'s key financial metrics?
Revolution Medicines, Inc. has a market capitalization of $18.3B. Return on equity stands at -58.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.